Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$15.24 USD
-0.72 (-4.51%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $15.25 +0.01 (0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SYRE 15.24 -0.72(-4.51%)
Will SYRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
Other News for SYRE
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight
Spyre Therapeutics GAAP EPS of -$0.49 beats by $0.28
Spyre Therapeutics Inc (SYRE) Q2 2025 Earnings: EPS of -$0.49 Beats Estimate, Reports $36. ...
Spyre Therapeutics reports Q2 EPS (49c), consensus (71c)
First Week of August 15th Options Trading For Spyre Therapeutics (SYRE)